NGF and osteoarthritis: Subsequently, the European Commission authorized the use of the anti-NGFmAb bedinvetmab (approved as Librela in the European Union in 2020) for the alleviation of osteoarthritis pain in dogs2 and the anti-NGF mAb frunevetmab (approved as Solensia in 2021 in the European Union & the UK) for cats with OA.3